PCM
AGIO icon

Penserra Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Penserra Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,355
Closed -$62K – 1350
2021
Q3 		$62K Sell
1,355
-45
-3% -$2.17K ﹤0.01% 981
2021
Q2 		$77K Sell
1,400
-170
-11% -$9.51K ﹤0.01% 873
2021
Q1 		$81K Sell
1,570
-30
-2% -$1.49K ﹤0.01% 720
2020
Q4 		$69K Buy
1,600
+1,010
+171% +$39.9K ﹤0.01% 643
2020
Q3 		$20K Buy
+590
New +$25.9K ﹤0.01% 739
2017
Q1 		– Sell
-420
Closed -$17K – 553
2016
Q4 		$17K Buy
420
+75
+22% +$3.94K ﹤0.01% 698
2016
Q3 		$18K Buy
345
+138
+67% +$6.01K ﹤0.01% 554
2016
Q2 		$9K Buy
207
+76
+58% +$3.75K ﹤0.01% 714
2016
Q1 		$5 Buy
131
+69
+111% +$2.95K ﹤0.01% 824
2015
Q4 		$4K Buy
+62
New +$4.07K ﹤0.01% 858

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Penserra Capital Management's AGIO Position: Q4 2021 in Review

Penserra Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 1,355 shares — an estimated $62K sold.

Penserra Capital Management first reported a position in AGIO in Q4 2015 and held it in 10 quarters. The position peaked at $81K in Q1 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

  • Penserra Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,355 Agios Pharmaceuticals shares in Q4 2021, an estimated $62K.
  • Penserra Capital Management first reported a position in Agios Pharmaceuticals in Q4 2015 and held it in 10 quarters.
  • Penserra Capital Management's Agios Pharmaceuticals position peaked at $81K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.